Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
University of California, Los Angeles · Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center" · +19 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
677
total citations
- FWCI
- 30.08
- Percentile
- 100%
- References
- 34
Citations per year
Authors
253Topics & keywords
Topics
Keywords
- Etoposide
- Tremelimumab
- Durvalumab
- Medicine
- Oncology
- Platinum
- Internal medicine
- Cancer
No related works found for this paper.